Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Votrient“
Suchtreffer
Begriffe & Kennungen
Votrient · 4.5 · Effect of concomitant use of pazopanib and simvastatin
Eintrag öffnenVotrient · 4.5 · Effect of food on pazopanib
Eintrag öffnenVotrient · 4.5 · Effects of other medicinal products on pazopanib
Eintrag öffnenVotrient · 4.5 · Effects of pazopanib on other medicinal products
Eintrag öffnenVotrient · 4.5 · In vitro studies suggested that the oxidative metabolism of pazopanib in human liver microsomes is mediated pr
Eintrag öffnenVotrient · 4.5 · In vitro studies with human liver microsomes showed that pazopanib inhibited CYP enzymes 1A2, 3A4, 2B6, 2C8, 2
Eintrag öffnenVotrient · 4.5 · In vitro, pazopanib inhibited human organic anion transporting polypeptide (OATP1B1). It cannot be excluded th
Eintrag öffnenVotrient · 4.5 · Medicinal products that raise gastric pH
Eintrag öffnenVotrient · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenVotrient · 4.8 Undesirable effects · 1
Eintrag öffnenVotrient · 4.8 · 11 Categories have been assigned based on absolute frequencies in the clinical trial data. Post-marketing data
Eintrag öffnenVotrient · 4.8 · 12 Very common Dysgeusiac 254 (22%) 1 (<1%) 0 Headache 122 (11%) 11 (<1%) 0 Common Dizziness 55 (5%) 3 (<1%) 1
Eintrag öffnenVotrient · 4.8 · 13 Very common Diarrhoea 614 (53%_) 65 (6%) 2 (<1%) Nausea 386 (34%) 14 (1%) 0 Vomiting 225 (20%) 18 (2%) 1 (<
Eintrag öffnenVotrient · 4.8 · 14 Very common Hair colour change 404 (35%) 1 (<1%) 0 Palmar-plantar 206 (18%) 39 (3%) 0 erythrodysaesthesia s
Eintrag öffnenVotrient · 4.8 · 15 Very common Alanine 246 (21%) 84 (7%) 14 (1%) aminotransferase increased Aspartate 211 (18%) 51 (4%) 10 (<1
Eintrag öffnenVotrient · 4.8 · 16 Table 3 Treatment-related adverse reactions reported in STS studies (n=382) or during post- marketing perio
Eintrag öffnenVotrient · 4.8 · 17 Common Epistaxis 22 (6%) 0 0 Dysphonia 20 (5%) 0 0 Dyspnoea 14 (4%) 3 (<1%) 0 Cough 12 (3%) 0 0 Pneumothora
Eintrag öffnenVotrient · 4.8 · 18 Very common Hair colour change 93 (24%) 0 0 Skin hypopigmentation 80 (21%) 0 0 Exfoliative rash 52 (14%) 2
Eintrag öffnenVotrient · 4.8 · 19 Very common Weight decreased 86 (23%) 5 (1%) 0 Common Ear, nose and throat 29 (8%) 4 (1%) 0 examination abn
Eintrag öffnenVotrient · 4.8 · Adverse drug reactions, all grades, which were reported in RCC and STS subjects or during the post-marketing p
Eintrag öffnen